Marker Therapeutics, Inc. (MRKR)

Marker Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	15.11	11.78	43.5	21.35	43.9
Cash & Cash Equivalents	15.11	11.78	43.5	21.35	43.9
Cash Growth	28.26%	-72.91%	103.71%	-51.37%	-28.90%
Receivables	1.03	2.4	0	1	0
Other Current Assets	0.99	2.44	2.48	2.06	1.58
Total Current Assets	17.13	16.62	45.98	24.41	45.49
Property, Plant & Equipment	0	0	22.15	21.2	0.87
Other Long-Term Assets	0	17.8	0	0	0
Total Long-Term Assets	0	17.8	22.15	21.2	0.87
Total Assets	17.13	34.42	68.14	45.61	46.36
Accounts Payable	3.07	2.52	11.13	6.01	1.76
Deferred Revenue	0	0	1.15	0	0
Current Debt	0	0	0.62	0.39	0.2
Other Current Liabilities	0	5.26	0	0	0.03
Total Current Liabilities	3.07	7.78	12.9	6.4	1.99
Long-Term Debt	0	0	11.25	11.87	0.28
Other Long-Term Liabilities	0	7.04	0	0	0
Total Long-Term Liabilities	0	7.04	11.25	11.87	0.28
Total Liabilities	3.07	14.82	24.15	18.27	2.27
Total Debt	0	0	11.87	12.26	0.48
Debt Growth	-	-	-3.17%	2430.50%	-
Retained Earnings	-436.29	-428.05	-398.12	-356.24	-327.53
Shareholders' Equity	14.05	19.6	43.99	27.34	44.09
Net Cash / Debt	15.11	11.78	31.63	9.1	43.42
Net Cash / Debt Growth	28.26%	-62.75%	247.76%	-79.05%	-29.68%
Net Cash Per Share	1.72	1.41	4.13	1.93	9.52
Working Capital	14.05	8.84	33.08	18.01	43.49
Book Value Per Share	1.59	2.35	5.75	5.81	9.67

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).